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via Complement, Immunoglobulin, TLR4, and Inflammatory
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Jie Du,1 Jie Xia,1 Maoping Chu,4 and Xingti Hu1,5
Abstract—Lung ischemia-reperfusion injury (LIRI) is still an unsolved medical issue, which negatively
affects the prognosis of many lung diseases. The aim of this study is to determine the effects of RvD1 on
LIRI and the potential mechanisms involved. The results revealed that the levels of complement,
immunoglobulin, cytokines, sICAM-1, MPO, MDA, CINC-1, MCP-1, ANXA-1, TLR4, NF-κBp65,
apoptosis index, and pulmonary permeability index were increased, whereas the levels of SOD, GSH-
PX activity, and oxygenation index were decreased in rats with LIRI. Except for ANXA-1, these
responses induced by LIRI were significantly inhibited by RvD1 treatment. In addition, LIRI-induced
structure damages of lung tissues were also alleviated by RvD1 as shown by H&E staining and
transmission electron microscopy. The results suggest that RvD1 may play an important role in
protection of LIRI via inhibition of complement, immunoglobulin, and neutrophil activation; down-
regulation of TLR4/NF-κB; and the expression of a variety of inflammatory factors.
KEYWORDS: resolvin; lung ischemia/reperfusion injury; complement; immunoglobulin; inflammation; oxidative
stress.
INTRODUCTION
Lung ischemia–reperfusion injury (LIRI) is still
an unsolved medical issue both in research and clinic
[1, 2]. LIRI is associated with the lung transplant,
extracorporeal circulation, post-enucleation of pulmo-
nary embolism, and pneumonectomy, which could
result in pulmonary dysfunction and severe damages
[3, 4]. The pathogenesis of LIRI has been studied for
many years. In this respect, oxygen radicals, inflam-
matory mediators, and neutrophils have been identi-
fied to play important roles in ischemia–reperfusion
injury (IRI) [5]. More recently, LIRI has been con-
sidered as a congenital autoimmune reaction [6].
Indeed, ischemia-exposed antigens on the membrane
could bind with the toll-like receptor 4 (TLR4) dur-
ing reperfusion and activate the related immune re-
sponse [7]. In addition, the ischemic antigen could
also bind with the plasma-specific immunoglobulin
and form immune complexes to promote the inflam-
matory reaction and aggravate the lung injury [8].
Maoping Chu and Xingti Hu contributed equally to this work.
Electronic supplementary material The online version of this article
(doi:10.1007/s10753-016-0364-9) contains supplementary material,
which is available to authorized users.
1 The Children’s Department of Cardiovascular and Thoracic Surgery,
Children’s Heart Center, The Second Affiliated Hospital and Yuying
Children’s Hospital, Institute of Cardiovascular Development and Trans-
lational Medicine, Wenzhou Medical University, Wenzhou, 325027,
People’s Republic of China
2Wuhan Medical & Healthcare Center for Woman and Children, Wuhan,
People’s Republic of China
3 The Children’s Department of Respiration Medicine, The Second Affil-
iated Hospital and Yuying Children’s Hospital, Wenzhou Medical Uni-
versity, Wenzhou, 325027, People’s Republic of China
4 The Children’s Department of Cardiovascular Medicine, Children’s Heart
Center, the Second Affiliated Hospital and Yuying Children’s Hospital,
Institute of Cardiovascular Development andTranslationalMedicine,Wen-
zhou Medical University, Wenzhou, 325027, People’s Republic of China
5 To whom correspondence should be addressed at The Children’s Depart-
ment of Cardiovascular and Thoracic Surgery, Children’s Heart Center,
The Second Affiliated Hospital and Yuying Children’s Hospital, Institute
of Cardiovascular Development and Translational Medicine, Wenzhou
Medical University, Wenzhou, 325027, People’s Republic of China. E-
mail: huxingti@126.com
0360-3997/16/0400-1319/0 # 2016 The Author(s). This article is published with open access at Springerlink.com
Inflammation, Vol. 39, No. 4, August 2016 (# 2016)
DOI: 10.1007/s10753-016-0364-9
1319
Identifying effective and safety methods/drugs to re-
duce the damages of LIRI is still a hot research area. The
anti-inflammatory effect of endogenous lipid mediators,
such as resolvin (Rv) and lipoxin, has been tested in many
studies [9–11]. These specialized pro-resolving mediators
have the conserved structures with the synthesized biolog-
ical functions in host defense, pain, organ protection, and
tissue remodeling [12, 13], which could protect several
organs such as the brain, lung, kidney, and stomach from
IRI [14–18]. However, the effect of Rv on LIRI is still
unclear.
In the present study, we aimed to investigate the effect
and the related mechanism of resolvin D1 (RvD1) on LIRI
in rats. In particular, we studied the effects of RvD1 on the
change of complement, immunoglobulin protein, TLR4,
nuclear factor kappaB (NF-κB) p65, inflammatory re-
sponse, oxidative stress, the pathological structure, and
the pulmonary function in rats.
MATERIALS AND METHODS
Rat Model of LIRI
All animal protocols were approved by the Institu-
tional Animal Care and Use Committee at Wenzhou Med-
ical University and were consistent with the Guide for the
Care and Use of Laboratory Animals (updated (2011)
version of the NIH guidelines). Sprague Dawley (SD)male
rats (8 weeks old, 200 to 250 g) were fed with a standard
diet and maintained in a controlled environment of the
animal center at 25±1 °C under a 12-h light–dark cycle.
Rats were anesthetized by an intraperitoneal injection
of 10 % chloral hydrate (300 mg/kg−1 body weight) and
placed in a supine position. The animals were then
intubated for artificial ventilation with oxygen using a
small animal breathing machine (tidal volume 5 ml,
frenquency 70 per min) and electrocardiograph monitor.
Thoracotomy was performed at the anterior lateral side of
the left fourth intercostal. The muscular layer and pleura
were gently dissected to expose the heart and lung. After
that, the hilum of left lung was dissociated and the artery
clamp was used to pass through the hilum of lung from the
upper right to the lower left. The whole clamped left hilum
was clearly exposed by slightly stirring up the clamp.
Before blocking, heparin was injected intravenously
(1 mg/kg body weight). After ischemia for 45 min, the
artery clamp was removed (no blocking in sham group)
and then reperfusion was started and lasted for 150 min.
During the reperfusion time, 0.5 ml normal saline (NS) was
injected intravenously every hour to maintain the body
fluid. After that, the chest wall was closed, the animal
was extubated, and the body temperature was maintained
using a warming plate.
Animal Grouping and Treatments
RvD1 (C22H32O5, 7S,8R, 17S-trihydroxy-4Z, 9E,
11E, 13Z, 15E, 19Z-docosahexaenoicacid; see Supplemen-
tary Fig. 1 in the Supplementary Material) was purchased
from Cayman Chemical Company, Ann Arbor, USA (cat.
number 10012554). Forty-eight SD rats were randomly
divided into four groups (12 rats/group) as follows: (1) sham
group: no blocking of hilum in left lung; (2) ischemia-
reperfusion (IR)-control (C) group: blocking for 45 min
and reperfusion for 150 min; (3) IR-NS group: blocking
for 45 min, reperfusion for 10 min followed by injection of
2 ml/kg NS by formal vein and continuous reperfusion for
140 min; (4) IR-RV group: blocking for 45 min, reperfusion
for 10 min followed by injection of 100 μg/kg RvD1 by
formal vein, and continuous reperfusion for 140 min.
Blood, Bronchoalveolar Lavage Fluid Collection,
and Tissue Harvest
Blood samples were collected in each group immedi-
ately before thoracotomy (T1) or after the experiments (T2).
In the sham group, T2 was obtained after 195 min of the
artery clip across the left hilus pulmonis. For all other
groups, T2 blood samples were obtained after 150 min of
reperfusion. Rats were sacrificed after blood collection.
The bronchoalveolar lavage fluid (BALF) was then col-
lected by washing the airways of the left lungs three times
with a total of 5 ml of phosphate buffer solution through a
tracheal cannula (recovery rate >80 %), which was pooled
and centrifuged at 3000 rpm/min for 15min for further use.
The left lung tissue of rats was dissected to measure the wet
Abbreviations: LIRI, Lung ischemia-reperfusion injury; IRI, Ischemia–
reperfusion injury; IR, Ischemia–reperfusion; Rv, Resolvin; SD, Sprague
Dawley; BALF, Bronchoalveolar lavage fluid; HE, Hematoxylin–eosin;
TEM, Transmission electron microscopy; W, Wet weight; D, Dry weight;
PPI, Pulmonary permeability index; Ig, Immune globulin; IL, Interleukin;
TNF, Tumor necrosis factor; sICAM, Soluble intercellular adhesion mol-
ecule; CINC, Cytokine-induced neutrophil chemoattractant; MCP, Mono-
cyte chemoattractant protein; ANXA-1, Annexin-1; MPO,
Myeloperoxidase; GSH-PX, Glutathione peroxidase; SOD, Superoxide
dismutase; MDA, Malondialdehyde; RT-qPCR, Real-time quantitative
polymerase chain reaction; WB, Western blotting; TLR4, Toll-like recep-
tor 4; NF-κB, Nuclear factor kappaB; TUNEL, TdT-mediated dUTP nick
end labeling; AI, Apoptosis index; PMN, Polymorphonuclear neutrophils;
PVDF, Polyvinylidene fluoride; NS, Normal saline
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to dry weigh ratio (W/D) value. Other lung tissues were
fixed in 4 % paraformaldehyde or frozen in −70 °C refrig-
erator for further analysis.
Lung Tissue W/D
About 1 g of lung tissue was measured and named as
wet weight. The tissue was then kept in 70 °C electrother-
mal constant-temperature dry box for 48 h, and the weight
of tissue was designed as dry weight. W/D was calculated
and analyzed, which can be an indicator of the lung tissue
edema.
BALF Leukocyte Count, BALF Neutrophil Ratio
and Pulmonary Permeability Index
Samples of BALF precipitate were analyzed for the
number of leukocyte. Through wright staining, the BALF
neutrophil ratio was obtained. The supernatant of BALF
and blood serum was harvested for total protein analysis
using the Bradford method. The ratio of total protein in
BALF to the total protein in blood serum was calculated
and named as Pulmonary Permeability Index (PPI).
Oxygenation Index
The arterial blood gas analysis was performed at T2,
and the ratio of PaO2 to FiO2 was then obtained as an
oxygenation index.
Lung Tissue Hematoxylin–Eosin Staining
Lung samples obtained at T2 were fixed in 4 % para-
formaldehyde and subsequently embedded in paraffin.
Sections (5 μm thick) were stained with hematoxylin–
eosin (HE) using a standard protocol and analyzed by light
microscopy.
Transmission Electron Microscopy
Lung samples were dissected and immediately fixed
in 0.1 M phosphate buffer containing 2.5 % glutaraldehyde
and 2 % paraformaldehyde for 4 h. The samples were then
fixed with 1 % osmium tetroxide for 2 h, dehydrated
through a graded ethanol series, and embedded in epoxy
resin. Resin-embedded blocks were cut into 60∼80-nm
ultrathin sections with an ultramicrotome (PT-XL, RMC,
USA). The ultrathin sections were placed on carbon-coated
nickel grids and examined with an H-7500 transmission
electron microscope (H-7500, Tokyo, Japan).
Complement, Immune Globulin, Cytokine,
and Adhesion Molecule Levels
Blood samples were collected by femoral venipunc-
ture at set time points, before thoracotomy (T1) and after
reperfusion (T2). The serum was then analyzed by an
ELISA kit (Boyun Biotech, Shanghai, China) to determine
the levels of complements (C1q, C2, C3a, C4, C5a), im-
mune globulin (Ig)M and IgG, cytokines (interleukin (IL)-
1β, IL-6, tumor necrosis factor (TNF)-α), and soluble
intercellular adhesion molecule (sICAM)-1) in accordance
with the manufacturer’s instructions.
Cytokine-Induced Neutrophil Chemoattractant-1,
Monocyte Chemoattractant Protein-1, and Annexin-1
Determination
The lung tissue homogenate was centrifuged, and the
supernatant was used to determine the concentration of
cytokine-induced neutrophil chemoattractant (CINC)-1,
monocyte chemoattractant protein (MCP)-1, and annexin-
1 (ANXA-1) by an ELISA kit (Boyun Biotech, Shanghai,
China) according to the manufacturer’s instructions.
Myeloperoxidase, Superoxide Dismutase, Glutathione
Peroxidase Activity, and Malondialdehyde Content
Determination
The lung tissue myeloperoxidase (MPO) activity was
determined on frozen tissue by use of colorimetry assay
kits (Jiancheng Bioengineering Institute, Nanjing, China).
The lung tissue superoxide dismutase (SOD) and glutathi-
one peroxidase (GSH-PX) activity was determined on
frozen tissue using Xanthine Oxidase Assay kits
(Jiancheng Bioengineering Institute, Nanjing, China).
The malondialdehyde (MDA) content was determined on
frozen lung tissue by use of the thiobarbituric acid assay kit
(Jiancheng Bioengineering Institute, Nanjing, China).
Real-Time Quantitative Polymerase Chain Reaction
Analysis
Total RNAs of the tissues were extracted using
TRIzol Reagent (Invitrogen, USA) according to the man-
ufacturer’s instructions, and the total RNA concentrations
were quantified. Subsequently, 500 ng of total RNA was
reversed via the complementary DNA (cDNA) synthesis
kit (Invitrogen, USA). Real-time quantitative polymerase
chain reaction (RT-qPCR) was achieved using the SYBR
Green system (Bio-Rad, USA). Amplifications for cDNA
samples were carried out using a PCR machine in the
following conditions: 95 °C for 90 s, followed by 40 cycles
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(95 °C for 5 s and 58 °C for 30 s). Primer sequences of
TLR4 and NF-κBp65 are as shown on Table 1. The
relative quantification of target gene was normalized
to GAPDH and calculated using the absolute quanti-
fication standard curve method. Melting curve pro-
files were produced at the end of each PCR so as to
confirm the specific transcriptions of amplification.
Each sample was analyzed in triplicate.
Western Blotting Analysis
Lung tissues lysis was obtained using RIPA buffer
and then centrifuged to obtain the total protein. Equal
amounts of protein (50 μg) were subjected to SDS-PAGE.
Gels were transferred to polyvinylidene fluoride (PVDF)
membrane. Membrane was blocked with 5 % nonfat dry
milk in Tris-buffered saline, 0.1 % Tween 20 (Sigma,
USA), and immunoblotting was performed using TLR4
and NF-κBp65 rabbit anti-rat antibody (Cell Signaling
Technology, USA) as described by the manufacturer.
Anti-β-actin antibody (Santa Cruz Biotechnology, USA)
was used as loading control. Blots were then developed by
incubation with biotinylated anti-rabbit antibodies (Vector
Laboratories, USA) as secondary antibodies, followed by
incubation with ABC reagent (GE, USA). Signal was
detected using a luminescence kit (GE, USA) and X-ray
film.
TdT-Mediated dUTP Nick End Labeling Assay
Apoptosis was determined by TdT-mediated dUTP
nick end labeling (TUNEL) assay with TUNEL test kit
(Roche, USA) according to the manufacturer’s instruc-
tions. Cells with apoptotic morphologic features as well
as with tan or brown nuclei were judged to be apoptotic
cells. The five fields of view were automatically selected
by the Image-Pro Plus version 5.1 image analysis software.
The percentage of apoptosis-positive cells was calculated
for each field of view. The mean was calculated to obtain
the percentage of apoptotic cells and expressed as apoptotic
index (AI). AI (%)= (apoptotic nuclei count / total nucleus
count)× 100 %.
Statistical Analysis
Data are expressed as mean± standard deviation. Sta-
tistical analysis was performed by one-way ANOVA to
compare more than two groups or with two-tailed un-
paired-sample t test to compare two groups. All statistical
computations were performed using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). The significance level
was set at P<0.05.
RESULTS
The Effects of RvD1 on Lung Tissue W/D, BALF
Leukocyte Count, BALF Neutrophil Ratio, PPI,
and Oxygenation Index
Figure 1 shows the effects of RvD1 on the W/D,
BALF leukocyte count, BALF neutrophil ratio, PPI, and
oxygenation index in lung tissues. At the time point of T2,
the values of W/D, BALF leukocyte count, BALF neutro-
phil ratio, and PPI in IR-C, IR-NS, and IR-RV groups were
significantly higher than that in the sham group. Compared
to the IR-C group, these values in IR-RV group were
significantly reduced (P<0.05), whereas there was no
statistic difference between IR-NS group and IR-C group.
In terms of the oxygenation index, the sham group
had a higher value than other three groups did. Interesting-
ly, the index in the IR-RV group was also much higher than
that in the IR-C group (P<0.05). No difference was found
between IR-NS group and IR-C group.
Pathologic Changes of Lung Tissues
To further assess the effect of RvD1 on IRI of the
lung, we analyzed pathological changes by H&E staining
(Fig. 2a). In the sham group, the pulmonary alveoli and
interstitium remain intact with smooth thin alveolar wall
and uniform alveolar septal thickness. No apomorphosis,
exudation, and neutrophil infiltration were observed. In IR-
NS and IR-C groups, damaged alveoli structure and dilated
and congestive capillaries could be found. The thickened
interstitium was infiltrated with inflammatory cells, while
the alveolar lumen was also filled with exudates, red blood
Table 1. Real-Time PCR Primer Sequences
Gene Forward primer Reverse primer Size (bp)
TLR4 5 -TTATCCAGAGCCGTTGGTGT-3 5 -CCCACTCGAGGTAGGTGTTT-3 171 bp
NF-κBp65 5 -TTCCTGCTTACGGTGGGATT-3 5 -CCCCACAT CCTCTTCCTTGT-3 248 bp
GAPDH 5 -GAGACAGCCGCATCTTCTTG-3 5 -TGACTGTGCCGTTGAACTTG-3 224 bp
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cells, and neutrophils. These histological damages in the
IR-RV group were inhibited compared with those in IR-NS
and IR-C groups. In fact, less neutrophil infiltration and
only slight dilatation of the capillaries were observed in the
IR-RV group.
The ultrastructure of lung tissue was examined by
TEM, as shown in Fig. 2b. In the sham group, the lung
tissue ultrastructure was normal with tightly connected
pulmonary capillary endothelial cells, intact basement
membrane, and integral type I and type II alveolar epithe-
lial cells. The mitochondrial cristae, microvilli, and the
lamellar body were clear. However, the ultrastructure was
impaired in IR-C and IR-NS groups. The ultrastructure of
the lung tissue showed serious abnormalities with swelling
pulmonary capillary endothelial cells and mitochondria
and shrinking nuclear membrane. Less pinocytosis vesicles
can be seen in type I alveolar epithelial cells. Meanwhile,
decreased numbers of microvilli and scarce lamellar bodies
of the type II alveolar epithelial cells were observed, and a
large number of inflammatory cells infiltrated the alveolar
septum and capillaries. In the IR-RV group, the decreased
injuries were found compared to IR-C and IR-NS groups.
The pulmonary capillary endothelial cells and mitochon-
dria exhibited slight swelling. More pinocytosis vesicles
were seen in type I alveolar epithelial cells, and the in-
creased number ofmicrovilli and lamellar bodies were seen
in type II alveolar epithelial cells. In addition, the alveolar
septum had no obvious inflammatory cell infiltration in the
IR-RV group.
The Effects of RvD1 on Serum Levels of C1q, C2, C3a,
C4, and C5a
The serum levels of C1q, C2, C3a, C4, and C5a were
shown in Fig. 3. At T1, no difference was found among all
the groups. However, at time point of T2, the sham group
showed obviously lower level of all the complements than
the IR-C and IR-NS groups did. Obviously, the IR-RV
group exhibited decreased levels of C1q, C2, C3a, C4,
and C5a when compared to the IR-C group (P<0.05).
The Effects of RvD1 on Serum Levels of IgM and IgG
There was no significant difference in IgG and IgM
concentrations among all the groups at T1 (Fig. 4). At T2,
Fig. 1. The effects of RvD1 on lung tissueW/D, BALF leukocyte count, BALF neutrophil ratio, PPI, and oxygenation index. Comparison of lung tissueW/
D, BALF leukocyte count, BALF neutrophil ratio, PPI, and oxygenation index at T2 among all groups. At time point T2, lung tissue, BALF, and arterial blood
were collected immediately after the IR procedure was completed. W/D, BALF leukocyte count, BALF neutrophil ratio, PPI, and oxygenation index were
measured as described in BMATERIALSANDMETHODS^ section. aW/D, bBALF leukocyte count, cBALF neutrophil ratio, d PPI, e oxygenation index.
Data were expressed as means ± SD and analyzed by ANOVA and unpaired-sample t test. n = 12 for each group *P < 0.05 for comparisons of IR-C, IR-NS,
and IR-RV groups with sham group; #P < 0.05 for comparisons of IR-NS and IR-RV groups with IR-C group.
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the levels of IgG and IgM in IR-C and IR-NS groups were
significantly higher than that in the sham group. Compared
to the IR-C group, decreased levels of these two immune
globulins in the IR-RV group were found (P<0.05).
The Effects of RvD1 on Serum Levels of IL-1β, IL-6,
TNF-α, and sICAM-1
The levels of IL-1β, IL-6, TNF-α, and sICAM-1
showed similar trends to the levels of IgM and IgG. As
shown in Fig. 5, we found that no change happened at time
T1. At T2, the IL-1β, IL-6, TNF-α, and sICAM-1 concen-
trations in IR-C and IR-NS groups were much higher than
those in the sham group. A remarkable decrease was found
in the IR-RV group when compared to the IR-C group
(P<0.05). However, no difference was seen between the
IR-C group and the IR-NS group.
The Effects of RvD1 on CINC-1, MCP-1, and ANXA-1
Content in Lung Tissues
All the IR groups showed higher values of CINC-1,
MCP-1, and ANXA-1 content than the sham group. As
shown in Fig. 6, compared to IR-C, significantly decreased
levels of CINC-1 and MCP-1, but elevated level of
ANXA-1, in the IR-RV group were observed (P<0.05).
The Effects of RvD1 on MPO, SOD, and GSH-PX
Activity and MDA Production in Lung Tissues
The values of MPO, SOD, GSH-PX, and MDA at T2
were exhibited in Fig. 7. We found that the values of MPO
and MDA in the IR groups were obviously higher than
those in the sham group. Among the three IR groups, the
IR-RV group showed statistically lower values than did the
IR-C group (P< 0.05). As for the SOD and GSH-PX
levels, the IR-C and IR-NS groups presented decreased
status than did the sham group, but no difference was found
between the sham group and the IR-RV group.Meanwhile,
those two levels were elevated, and significantly higher
levels were found in the IR-RV group when compared to
the IR-C group (P<0.05).
The Effects of IR and RvD1 Treatment on TLR4
and NF-κBp65 Gene Expression
The results of the TLR4 and NF-κBp65 expressions
at T2 in lung tissue were shown in Fig. 8. Compared to the
sham group, the messenger RNA (mRNA) levels of TLR4
and NF-κBp65 in IR-C and IR-NS groups were signifi-
cantly increased (P<0.05). We found that these two genes
in the IR-RV group showed a comparable level to the genes
in the IR-C group (P<0.05). No change was found be-
tween IR-C group and IR-NS group.
Western Blot Analysis of TLR4 and NF-κBp65 Protein
Expression
The levels of LR4 and NF-κBp65 proteins were
remarkably elevated in IR-C and IR-NS groups when
compared to the sham group (Fig. 9). Significantly,
the decreased levels of TLR4 and NF-κBp65 in the
IR-RV group were found compared to the IR-C
group (P< 0.05).
Fig. 2. Pathologic changes of lung tissues was examined by H&E staining
and TEM. The lung tissue sections were from the following groups of a-
nimals: sham, aham group; IR-C, IR-C group; IR-NS, IR-NS group; and
IR-RV, IR-RV group. aH&E staining of lung tissue sections from different
groups (scale bars: 100 μm,magnification ×100). b Transmission electron
microscopy (TEM) of lung tissue sections from different groups (magni-
fication ×15000).
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Inhibitory Effect of RvD1 on LIRI-Induced Cell
Apoptosis
The effect of RVD1 on lung tissue cell apoptosis
at T2 was determined and was shown in Fig. 10. The
AI of all the three groups were obviously higher than
that in the sham group. Among the three IR groups, the
index in the IR-RV group was statistically decreased
when compared to other two IR groups (P < 0.05);
however, no difference was found between IR-C and
IR-NS group.
Fig. 3. The effects of RvD1 on serum levels of C1q, C2, C3a, C4, and C5a. Comparison of concentrations of serum C1q, C2, C3a, C4, and C5a at T1 and T2
among all groups. At time point T1, blood was collected immediately before thoracotomy. At time point T2, blood was collected right after the IR procedure
was over. a C1q, b C2, c C3a, d C4, e C5a. Data were expressed as means ± SD and analyzed by ANOVA and unpaired-sample t test. n = 12 for each group.
*P < 0.05 for comparisons of IR-C, IR-NS, and IR-RV groups with sham group; #P < 0.05 for comparisons of IR-NS and IR-RV groups with IR-C group.
Fig. 4. The effects of RvD1 on serum levels of IgG and IgM. Comparison of concentrations of serum IgG and IgM at T1 and T2 among all groups. At time
point T1, blood was collected immediately before thoracotomy. At time point T2, blood was collected right after the IR procedure was over. a IgG, b IgM.
Data were expressed as means ± SD and analyzed by ANOVA and unpaired-sample t test. n = 12 for each group. *P < 0.05 for comparisons of IR-C, IR-NS,
and IR-RV groups with sham group; #P < 0.05 for comparisons of IR-NS and IR-RV groups with IR-C group.
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DISCUSSION
Rv is a newly found lipid molecule that can reduce the
inflammation and protect the tissue structure by restraining
the proliferation of neutrophils, macrophages, and other
inflammatory cells [19–21]. In chronic disease such as
the inflammatory bowel disease and rheumatoid arthritis,
Rv can inhibit humoral immunity and cellular immunity to
protect the patients [22, 23]. The animal model of skin
infection, gingivitis, peritonitis, and sepsis treated by Rv
can relieve the injuries, protect the organs, and increase the
survival rates of animals [24]. The research about the
Fig. 5. The effects of RvD1 on serum levels of IL-1β, IL-6, TNF-α, and sICAM-1. Comparison of concentrations of serum IL-1β, IL-6, TNF-α, and
sICAM-1 at T1 and T2 among all groups. At time point T1, blood was collected immediately before thoracotomy. At time point T2, blood was collected right
after the IR procedure was over. a IL-1β, b IL-6, c TNF-α, d sICAM-1. Data were expressed as means ± SD and analyzed by ANOVA and unpaired-sample t
test. n = 12 for each group. *P < 0.05 for comparisons of IR-C, IR-NS, and IR-RV groups with sham group; #P < 0.05 for comparisons of IR-NS and IR-RV
groups with IR-C group.
Fig. 6. The effects of RvD1 on CINC-1, MCP-1, and ANXA-1 content in lung tissues. Comparison of lung tissue CINC-1, MCP-1, and ANXA-1 content at
T2 among all groups. At time point T2, lung tissue was collected immediately after the IR procedure was completed and kept frozen in liquid nitrogen. CINC-
1, MCP-1, and ANXA-1 were measured as described in BMATERIALANDMETHODS^ section. aCINC-1, bMCP-1, cANXA-1. Data were expressed as
means ± SD and analyzed by ANOVA and unpaired-sample t test. n = 12 for each group. *P < 0.05 for comparisons of IR-C, IR-NS, and IR-RV groups with
sham group; #P < 0.05 for comparisons of IR-NS and IR-RV groups with IR-C group.
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protective effect of Rv on the IRI organs, for example,
heart and brain, has just been started [15, 25]. However,
the effects of RvD1 on LIRI are currently unknown.
The ultrastructure of the lung tissue can finely
reflect the pathological changes of the lung injury. In
the present study, we observed that the normal lung
ultrastructure was damaged by IR, exhibiting swelling
pulmonary capillary endothelial cells and mitochondria
and shrinking nuclear membrane with a large number of
inflammatory cells infiltrating in the alveolar septum
and capillaries (Fig. 2b). These abnormalities were also
found in the H&E staining sections, which showed the
destructive alveoli structure, dilated and congestive cap-
illaries, and inflammatory cells filling the thickened
Fig. 7. The effects of RvD1 onMPO, SOD, and GSH-PX activity andMDAproduction in lung tissues. Comparison of lung tissueMPO, SOD, and GSH-PX
activity andMDA production at T2 among all groups. At time point T2, lung tissue was collected immediately after the IR procedure was completed and kept
frozen in liquid nitrogen. MPO, SOD, and GSH-PX activity andMDAwere measured as described in BMATERIALSANDMETHODS^ section. aMPO, b
SOD, c GSH-PX, dMDA. Data were expressed as means ± SD and analyzed by ANOVA and unpaired-sample t test. n = 12 for each group. *P < 0.05 for
comparisons of IR-C, IR-NS, and IR-RV groups with sham group; #P < 0.05 for comparisons of IR-NS and IR-RV groups with IR-C group.
Fig. 8. The effects of I/R and RvD1 treatment on TLR4 and NF-κBp65 mRNA expression. Comparison of mRNA levels of TLR4 and NF-κBp65 of lung
tissues from rats of different groups at T2. Samples were collected right after IR procedure, and the frozen lung tissuemeasured as described in BMATERIALS
ANDMETHODS^ section. a TLR4, bNF-κBp65. Data were expressed as means ± SD and analyzed by ANOVA and unpaired-sample t test. n = 12 for each
group. *P < 0.05 for comparisons of IR-C, IR-NS, and IR-RV groups with sham group; #P < 0.05 for comparisons of IR-NS and IR-RV groups with
IR-C group.
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interstitium (Fig. 2a). Moreover, the elevated BALF
leukocyte count, BALF neutrophil ratio, W/D, and PPI
and the decreased level of oxygenation index were also
found in the ischemic reperfusion rats. All these above
results are potent evidences of the IRI and pulmonary
dysfunctions. Through the treatment of RvD1, less
structure changes, neutrophil infiltration, and cell apo-
ptosis; lower PPI; and increased oxygenation index
were shown in the IR-RV group, indicating a protective
effect of RvD1 on lung tissue.
The occurrence of LIRI has become more frequent in
clinical practice during the past decades. In recent years,
the research of LIRI has been focused on the following
aspects: oxygen radicals and lipid peroxidation [26, 27],
excessive inflammatory response caused by neutrophil
infiltration [28, 29], body fluid and cellular factors [30],
Fig. 9. Western blot analysis of TLR4 and NF-κBp65 protein expression. Comparison of protein levels of TLR4 and NF-κBp65 of lung tissues from rats of
different groups at T2. Samples were collected right after IR procedure was over and western blot was performed as described in BMATERIALS AND
METHODS^ section. β-Actin was used as a loading control. (1) Western blotting: a TLR4, b NF-κBp65. (2) Quantitative data of western blot: a TLR4, b
NF-κBp65. Data were expressed asmeans ± SD and analyzed by ANOVA and unpaired-sample t test. n = 12 for each group. *P < 0.05 for comparisons of IR-
C, IR-NS, and IR-RV groups with sham group; #P < 0.05 for comparisons of IR-NS and IR-RV groups with IR-C group.
Fig. 10. Inhibitory effect of RvD1 on LIRI-induced cell apoptosis. The detection of cell apoptosis in lung tissues from rats of different groups at T2.
Apoptosis was determined by TUNEL assay according to manufacturer’s instructions as described in BMATERIALS ANDMETHODS^ section. Cells with
apoptotic morphological features and with tan or brown nucleiwere judged to be apoptotic cells. a TUNEL assay, group sham: a small amount of apoptotic
cells in lung tissue; group IR-C and group IR-NS: apoptotic cells in lung tissue increased significantly; group IR-RV: apoptotic cells were between group
sham and group IR-C. b Apoptosis index (apoptotic nuclei count/total nucleus count) was represented with histogram. Data were expressed as means ± SD
and analyzed by ANOVA and unpaired-sample t test. n = 12 for each group. *P < 0.05 for comparisons of IR-C, IR-NS, and IR-RV groups with sham group;
#P < 0.05 for comparisons of IR-NS and IR-RV groups with IR-C group.
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imbalance of intracellular calcium homeostasis [31],
and cell apoptosis [32]. Among all the five aspects,
the immune reaction might be the most critical factor
for the pathogenesis of LIRI. Thrane et al. [6] re-
ported that LIRI was a congenital autoimmune reac-
tion. Under the ischemic condition, antigens were
exposed and combined with the immune globulin to
form the immune complex and activate the comple-
ments [8, 33], which could generate a series of
bioactive fragments like C3a and C5a and further
promote the inflammatory response [34, 35].
LIRI, characterized by nonspecific alveolar damage,
hypoxemia, lung edema, and pulmonary hemorrhage, has a
direct impact on the prognosis of many related disease,
such as the pneumonectomy and the lung transplantation.
IR causes lung injury by a variety of reasons.We found that
the levels of IgM and IgG and the complements C1q, C2,
C3a, C4, and C5a were increased by LIRI. However, after
the use of RvD1, they were down-regulated and the dam-
age of lung tissue was alleviated, suggesting that the pro-
tective effect of RvD1 was associated with its inhibiting
effect on the immune globulin and complements. Tang et
al. [36] also presented that i.v. administration of either AT-
RvD1 or p-RvD1 caused significant decreases in the BALF
contents of neutrophils, inflammatory cytokines,
chemokines, and complement C5a. These results suggest
a new approach to blocking of immune complex-induced
inflammation and protecting for lung injury. Other studies
also demonstrated that the inhibition of immune globulins
and complements can alleviate the reperfusion injury of
organs [37–39]. The Cr2−/− [40] and RAG−/− [41] immu-
nodeficient mice showed slight IRI due to their incapability
of synthesizing IgM. Besides, the level of IRI was aggra-
vated when the mice were treated with IgM or anti-
phospholipid antibodies [42, 43]. In addition, LIRI could
activate the complement and produce fragments like C3a
and C5a, which are important proinflammatory mediators
and chemokines, and could recruit the polymorphonuclear
neutrophils (PMNs) to the injury sites. Bless et al. [35]
reported that the CINC and MIP-2 as well as the comple-
ment activation product C5a were required for lung neu-
trophil recruitment and full induction of lung injury after
hindlimb IR in rats. Inhibition of PMN-mediated inflam-
mation can reduce the LIRI [44]. RvD1 is a tissue
inflammation-subsided agonist, and its functions are recep-
tor dependent [20, 45]. After LIRI, we applied RvD1 and
found less infiltration of PMN in the lung tissue and
decreased level of MPO, BALF leukocyte count, and
BALF neutrophil ratio, which may be related to the effect
of RvD1 on inhibiting complement activation, reducing
sICAM-1 and CINC-1 secretion, and promoting ANXA-l
expression.
Recent studies have shown that TLR4 plays a key role
in the inflammatory cascade of the LIRI [46, 47]. Less
damage was found in TLR4-deficient (TLR4 −/−) mice
than in wild-type mice (C57BL/6J) in LIRI [48]. NF-κB is
a downstreammolecule of the TLR4 cascade, which is also
important for the autoimmune regulation. The changes of
the variety of pro-inflammatory factors, chemokines, ad-
hesion molecules, and enzymes involved in IRI were de-
pendent on the activation of NF-κB [49].
Uncontrolled inflammation usually exists in LIRI.
The cellular and molecular changes are controlled by the
huge cytokine network. Studies showed that the transcrip-
tional product of NF-κB was the main inflammatory me-
diator and cytokine in the inflammatory reaction of LIRI,
and NF-κB may be the key for the regulation of inflam-
matory reaction [50]. Thus, NF-κB can affect the LIRI at
the transcriptional level by its effects on the inflammatory
mediators. Others also showed that LIRI promoted the
release of various inflammatory factors, including TNF-
α, IL-1, IL-4, IL-6, IL-8, IL-10, and IL-12 [30, 51, 52].
Sharma et al. [53] considered that alveolar macrophages
produced TNF-α when experiencing LIRI, which further
promoted epithelial cells to release the chemokine, such as
KC, MCP-1 and MIP-2, RANTES, and IL-6, and aggra-
vated the injury through neutrophils recruiting under the
stimulation of chemokine. Ito et al. [54] found that LIRI
increased the concentrations of TNF-α and CINC-1 of the
lung tissue. The CINC-1 of rats, corresponding to the
human IL-8 family members in the structure and function,
has strong effects on the chemotaxis and activation of the
neutrophils [49]. However, ANXA-1 has an opposite ef-
fect. In vitro and in vivo experiments confirmed that
through inhibiting the neutrophil adhesion, migration, and
the production of proinflammatory mediators and superox-
ide, endogenous or exogenous ANXA-l can promote the
phagocytosis and apoptosis of PMN and further play an
important role in anti-inflammation [55, 56].
Our results showed that the cytokines levels of IL-
1β, IL-6, TNF-α, and sICAM-1; inflammatory factors
levels of CINC-1, MCP-1, and ANXA-1; and the
mRNA level and protein expression of TLR4 and NF-
κBp65 were up-regulated under LIRI. The results sug-
gest that the TLR4/NF-κB pathway was activated with
the increased release of inflammatory factors, adhesion
molecules, and chemokine. Moreover, it has been found
that Rv participated in the regulation of the NF-κB
pathway [57, 58] and NF-κB was the important signal-
ing molecule and intermediate link of Rv biological
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effect [59]. RvD1 could decrease the NF-κB-
phosphorylated p65 nuclear translocation and inhibit
expression of the cytokines and chemokines (TNF-α,
IL-1β, IL-6, CINC-1, MCP-1, etc.) during the inflam-
matory cascade [60–63]. The inflammatory reaction is
one of the vital features of LIRI, and the results of this
study were similar with the above previous studies after
using RvD1 [60–63]. Specifically, the cytokines and
adhesion molecule of IL-1β, IL-6, TNF-α, and
sICAM-1 were notably reduced and the inflammatory
mediators of CINC-1 and MCP-1 were decreased but
with increased levels of ANXA-1, indicating that the
inflammatory condition and lung damage were distinct-
ly relieved.
Inflammation is associated with an oxidative stress
reaction, which has a positive feedback on inflammation
itself [64]. The results of this experiment showed that the
level of MDA, representing the degree of lipid peroxida-
tion and the attack of oxygen radicals [65], was signifi-
cantly increased in LIRI. However, the activity of SOD and
GSH-PX, indirectly reflecting the body’s ability to remove
the oxygen radicals [66], was significantly reduced. The
results suggested that the decreased ability of scavenging
free radicals is also related to the lung damage after LIRI.
RvD1 can relieve the injury induced by oxidative stress
[64] and protect against oxidative stress-initiated inflam-
mation [67]. In our study, RvD1 significantly improved the
SOD and GSH-Px activity, indicating that the scavenging
ability of the oxygen free radical was enhanced. Mean-
while, the reduced MDA level confirmed that RvD1 can
reduce the free radical-induced lung tissue damage and
help to restore the body’s oxygen/antioxidant balance.
LIRI increased the apoptosis of lung cells [32], and anti-
oxidative and anti-inflammatory treatment could reduce
the IR-induced lung cell apoptosis [68]. Our results
showed that RvD1 can significantly reduce the apoptosis
of lung tissue after LIRI, which may be associated with the
effect of RvD1 on inhibiting the oxidative stress and
inflammation.
RvD1 mainly plays a role in the inflammatory pro-
cess, but it would not participate in the maintenance of the
physiological functions. Therefore, this new type of anti-
inflammatory drug may not interfere with the body’s nor-
mal physiological activity and cause no obvious adverse
reaction. However, the unstable property, short half-life
and high price, the unknown dosage and the administrating
timing, the frequency, and the delivery ways would limit its
application. Thus, the development of the stable analogue
of RvD1 may eventually achieve the purpose of clinical
use. Further studies are needed to investigate the potential
harm of RvD1 to the immune protective function caused
by the inhibitory effect on the complement system, espe-
cially when suffering from the surgery and other injuries.
This experiment did not detect the dynamic changes
of the complement system during LIRI, and it is still
needed further study to explore the effect of comple-
ment after LIRI by using gene-deficient or gene
knockout animals. In addition, the lung tissue has a
dual blood supply system and can directly obtain
oxygen by pulmonary ventilation, which makes LIRI
different from other organs’ IRI [69]. The reported
models and our animal models of LIRI were
achieved by blocking and then loosening the pulmo-
nary hilus, which blocked not only the pulmonary
artery but also the bronchus and bronchial artery,
leading to the difference from the clinical LIRI.
Much effort is still needed to improve the animal
model of LIRI and make it closer to clinical practice.
CONCLUSIONS
In conclusion, RvD1 is able to restrain the serum
levels of complements and immunoglobulin; inhibit the
neutrophil activation; down-regulate the mRNA and pro-
tein expression of TLR4 and NF-κB P65; and inhibit the
expression of a variety of inflammatory cytokines, chemo-
tactic factors, and adhesion molecules to restore the
oxidation/antioxidation balance when suffering from LIRI.
Through those effects, the apoptosis and ultrastructure of
lung tissue can be protected, resulting in reduced lung
injury and improved lung function.
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